This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phytopharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment.

The present invention relates to a pad for treating skin diseases, comprising agar gel and a fiber layer fixed to the inside of the gel, and a manufacturing method therefor. The pad of the present invention inhibits blood vessel exudation symptoms according to vasodilation by maintaining a low temperature of the affected area, reduces an itchy sensation and, at the same time, removes, from the skin, plasma proteins and various plasma-derived substances accumulated in skin tissue, thereby having an effect of alleviating the symptoms of the affected area.

The present invention is directed to a flowable hemostatic paste comprising a crosslinked carboxymethyl cellulose and at least one non-toxic dispersant. More specifically the present invention relates to a hemostatic paste containing citric acid cross-linked CMC, which is suspended or dispersed as a powder in a mixture of a first non-toxic glycerol-containing hygroscopic dispersant and a second non-toxic alcohol functionalized dispersant comprising propylene glycol or 1,3-butanediol.

The disclosed technology relates to a wound dressing comprising a vertically lapped material. The disclosed technology further relates to methods and uses of the wound dressing.

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting pre-mixed fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

Disclosed and described herein are systems and methods energy generation from fabric electrochemistry. An electrical cell is created when electrodes (cathodes and anodes) are printed on or otherwise embedded into fabrics to generate DC power when moistened by a conductive bodily liquid such as sweat, wound, fluid, etc. The latter acts, in turn, as the cell's electrolyte. A singular piece of fabric can be configured into multiple cells by dividing regions of the fabric with hydrophobic barriers and having at least one anode-cathode set in each region. Flexible inter-connections between the cells can be used to scale the generated power, per the application requirements.

A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Single layered nonwoven wound dressings containing (1) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (2) about 5% by weight to about 95% by weight (e.g., 5% to 95%) bleached cotton fibers, and (3) about 5% by weight to about 60% by weight (e.g., 5% to 60%) hydrophobic fibers (e.g., polypropylene, nylon); all percentages adding up to 100 wt %. Also, multi-layered nonwoven wound dressings, containing (1) at least one inner layer containing (a) about 50% by weight to about 95% by weight (e.g., 50% to 95) non-scoured, non-bleached greige cotton fibers and (b) about 5% by weight to about 50% by weight (e.g., 5% to 50%) hydrophobic fibers, all percentages adding up to 100 wt %, and (2) at least one outer layer containing (a) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (b) about 5% by weight to about 95% by weight (e.g., 5% to 95%) bleached cotton fibers, and (c) about 5% by weight to about 60% by weight (e.g., 5% to 60%) hydrophobic fibers (e.g., polypropylene, nylon); all percentages adding up to 100 wt %.

The present disclosure provides a medical grade nanofibrillar cellulose hydrogel comprising plant-based chemically and enzymatically unmodified nanofibrillar cellulose hydrogel having a concentration of the nanofibrillar cellulose in the range of 1.4-3.4% by weight, the nanofibrillar cellulose having a number-average diameter of fibrils and/or fibril bundles of 100 nm or less, and a storage modulus in the range of 1-35 Pa. The present disclosure also provides a method for treating a subject in need of treatment of body with implantable material, and a method for manufacturing medical grade nanofibrillar cellulose hydrogel.

A vented wound dressing barrier includes one or more membrane layers with a plurality of vents. The vents are cut along a perimeter of the vents through the one or more membrane layers. Each vent having a connection portion uncut relative to the one or more membrane layers thereby forming a hinge configured to allow the vents to open for drainage when exposed to fluid underlying the vented wound dressing barrier. The plurality of vents is each cut along the perimeter without removal of any of the membrane layer. The one or more membrane layers with the plurality of vents has a surface for covering a wound, the surface area in the absence of a fluid pressing on the vents having no openings or voids which reduce the surface area of a vented wound dressing barrier area covering a wound.